Terms: = Germ cell tumor AND TBX3, TBX3-ISO, ENSG00000135111, 6926, O15119, XHL, UMS AND Treatment
31 results:
1. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.
Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A
Front Immunol; 2023; 14():1225140. PubMed ID: 37662962
[TBL] [Abstract] [Full Text] [Related]
2. The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
Jia SQ; Zhuo R; Zhang ZM; Yang Y; Tao YF; Wang JW; Li XL; Xie Y; Li G; Wu D; Chen YL; Yu JJ; Feng CX; Li ZH; Zhou RF; Yang RD; Yang PC; Zhou B; Wan XM; Wu YM; Jiao WY; Zhou NN; Fang F; Pan J
J Immunol Res; 2022; 2022():7945884. PubMed ID: 36438198
[TBL] [Abstract] [Full Text] [Related]
3. The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
Li X; Moreira DC; Bag AK; Qaddoumi I; Acharya S; Chiang J
Neuro Oncol; 2023 Apr; 25(4):750-760. PubMed ID: 36260562
[TBL] [Abstract] [Full Text] [Related]
4. Every other day stereotactic radiation therapy for the treatment of uveal melanoma decreases toxicity.
Yazici G; Kiratli H; Ozyigit G; Sari SY; Elmali A; Yilmaz MT; Koc I; Deliktas O; Gumeler E; Cengiz M; Zorlu F
Radiother Oncol; 2022 Nov; 176():39-45. PubMed ID: 36184996
[TBL] [Abstract] [Full Text] [Related]
5. Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: A systematic review and a data pooled analysis.
Buonanno F; Conson M; de Almeida Ribeiro C; Oliviero C; Itta F; Liuzzi R; Pacelli R; Cella L; Clemente S
Radiother Oncol; 2022 Jan; 166():15-25. PubMed ID: 34774654
[TBL] [Abstract] [Full Text] [Related]
6. Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates.
van Beek JGM; van Rij CM; Baart SJ; Yavuzyigitoglu S; Bergmann MJ; Paridaens D; Naus NC; Kiliç E
Acta Ophthalmol; 2022 Aug; 100(5):511-519. PubMed ID: 34529346
[TBL] [Abstract] [Full Text] [Related]
7. Translation of single-cell transcriptomic analysis of uveal melanomas to clinical oncology.
Strub T; Martel A; Nahon-Esteve S; Baillif S; Ballotti R; Bertolotto C
Prog Retin Eye Res; 2021 Nov; 85():100968. PubMed ID: 33852963
[TBL] [Abstract] [Full Text] [Related]
8. Development of new therapeutic options for the treatment of uveal melanoma.
Wang JZ; Lin V; Toumi E; Wang K; Zhu H; Conway RM; Madigan MC; Murray M; Cherepanoff S; Zhou F; Shu W
FEBS J; 2021 Nov; 288(21):6226-6249. PubMed ID: 33838075
[TBL] [Abstract] [Full Text] [Related]
9. Current molecular and clinical insights into uveal melanoma (Review).
Fallico M; Raciti G; Longo A; Reibaldi M; Bonfiglio V; Russo A; Caltabiano R; Gattuso G; Falzone L; Avitabile T
Int J Oncol; 2021 Apr; 58(4):. PubMed ID: 33649778
[TBL] [Abstract] [Full Text] [Related]
10. Presence and prevalence of UV related genetic mutations in uveal melanoma: similarities with cutaneous melanoma.
Goh AY; Ramlogan-Steel CA; Jenkins KS; Steel JC; Layton CJ
Neoplasma; 2020 Sep; 67(5):958-971. PubMed ID: 32305056
[TBL] [Abstract] [Full Text] [Related]
11. Uveal melanoma.
Jager MJ; Shields CL; Cebulla CM; Abdel-Rahman MH; Grossniklaus HE; Stern MH; Carvajal RD; Belfort RN; Jia R; Shields JA; Damato BE
Nat Rev Dis Primers; 2020 Apr; 6(1):24. PubMed ID: 32273508
[TBL] [Abstract] [Full Text] [Related]
12. Genetic Background of Iris Melanomas and Iris Melanocytic tumors of Uncertain Malignant Potential.
van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
[TBL] [Abstract] [Full Text] [Related]
13. Primary bilateral uveal melanoma: a population-based study and systematic review.
Scott JF; Vyas R; Galvin J; Gotow E; Fiessinger L; Gerstenblith AT; Gerstenblith MR
Clin Exp Ophthalmol; 2018 Jul; 46(5):502-510. PubMed ID: 29219254
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4.
Li Z; Li X; Xu L; Tao Y; Yang C; Chen X; Fang F; Wu Y; Ding X; Zhao H; Li M; Qian G; Xu Y; Ren J; Du W; Wang J; Lu J; Hu S; Pan J
Oncol Rep; 2017 Nov; 38(5):2705-2716. PubMed ID: 29048629
[TBL] [Abstract] [Full Text] [Related]
15. The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the tbx3 transcription factor.
Peres J; Kwesi-Maliepaard EM; Rambow F; Larue L; Prince S
Cancer Lett; 2017 Oct; 405():111-119. PubMed ID: 28757416
[TBL] [Abstract] [Full Text] [Related]
16. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
Bender C; Enk A; Gutzmer R; Hassel JC
Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409
[TBL] [Abstract] [Full Text] [Related]
17. Advances in the treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
[TBL] [Abstract] [Full Text] [Related]
18. The biology of uveal melanoma.
Amaro A; Gangemi R; Piaggio F; Angelini G; Barisione G; Ferrini S; Pfeffer U
Cancer Metastasis Rev; 2017 Mar; 36(1):109-140. PubMed ID: 28229253
[TBL] [Abstract] [Full Text] [Related]
19. Microinvasive tumor endoresection in combination with ocular stereotactic radiosurgery.
Sinyavskiy OA; Troyanovsky RL; Ivanov PI; Golovin AS; Tibilov AV; Solonina SN; Astapenko AM; Zubatkina IS
J Neurosurg; 2016 Dec; 125(Suppl 1):58-63. PubMed ID: 27903184
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Implications of tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma.
Walter SD; Chao DL; Feuer W; Schiffman J; Char DH; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):734-40. PubMed ID: 27123792
[TBL] [Abstract] [Full Text] [Related]
[Next]
